Wedbush Assumes Coverage on Idenix Pharmaceuticals Inc. (IDIX) at Outperform; Market Potential for IDX184 Makes For Attractive Takeover Candidate
Tweet
Share
E-mailGet Alerts IDIX Hot Sheet
Price: $24.50 --0%
Rating Summary:
1 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 7
Rating Summary:
1 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 7
Join SI Premium – FREE
Wedbush assumes coverage on Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) with a Outperform. PT $14.00 (from $16.00).
Analyst, Akiva Felt, said, "We are assuming coverage of Idenix with an OP rating and $14 fair value on the market potential for IDX184, the sole unpartnered clinical-stage nucleotide drug for HCV. Following the recent acquisitions of HCV nucleotide developers Pharmasset for $11.1B and Inhibitex for $2.5B, we continue to view IDIX as an attractive candidate for partnership or acquisition as IDX184 remains the only clinical-stage nucleotide candidate available for such transactions."
Wedbush adjusts FY12 EPS/Revs from (0.53)/$7.4mln to (0.27)/$40.1mln.
For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.
Shares of Idenix Pharmaceuticals Inc. closed at $10.15 yesterday.
Analyst, Akiva Felt, said, "We are assuming coverage of Idenix with an OP rating and $14 fair value on the market potential for IDX184, the sole unpartnered clinical-stage nucleotide drug for HCV. Following the recent acquisitions of HCV nucleotide developers Pharmasset for $11.1B and Inhibitex for $2.5B, we continue to view IDIX as an attractive candidate for partnership or acquisition as IDX184 remains the only clinical-stage nucleotide candidate available for such transactions."
Wedbush adjusts FY12 EPS/Revs from (0.53)/$7.4mln to (0.27)/$40.1mln.
For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.
Shares of Idenix Pharmaceuticals Inc. closed at $10.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BHP Group (BHP) Said to Weigh Potential Takeover of Anglo American (NGLOY) - Bloomberg
- Perrigo (PRGO) Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to EUR 275M
- IBM (IBM) Nears Acquisition of Software Provider HashiCorp (HCP) - WSJ
Create E-mail Alert Related Categories
Mergers and Acquisitions, New Coverage, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
